These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35063436)

  • 1. Corrigendum to "Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis" [Eur Urol Oncol 2021;4:927-42].
    Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
    Eur Urol Oncol; 2022 Aug; 5(4):480-481. PubMed ID: 35063436
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Ekaterina Laukhtina, Sung Ryul Shim, Keiichiro Mori, et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2021;4:927-42: Considerations for Interpreting Data Presented in Systematic Reviews and Network Meta-analyses of Urinary Biomarker Tests.
    Chiang CH; Chiang CH; Chiang CH
    Eur Urol Oncol; 2022 Apr; 5(2):263-264. PubMed ID: 35074283
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Sungmin Woo, Valeria Panebianco, Yoshifumi Narumi, Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 2020;3:306-315.
    Glykas I; Fragkoulis C; Kapogiannis F; Ntoumas K
    Eur Urol Oncol; 2020 Aug; 3(4):555-556. PubMed ID: 32536572
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
    Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
    Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Bründl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 2021;4:182-91: Image Analysis, Nuclear Abnormality Index, and Pattern Recognition Analysis.
    Cimadamore A; Lopez-Beltran A; Scarpelli M; Cheng L; Montironi R
    Eur Urol Oncol; 2021 Aug; 4(4):671-673. PubMed ID: 34144939
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply from authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2014;66:55-6.
    Leow JJ; Chang SL; Bellmunt J
    Eur Urol; 2014 Jul; 66(1):57-8. PubMed ID: 24568895
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF
    Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69-70: Towards Biomarker-Informed Management of Muscle-Invasive Bladder Cancer.
    Mouw KW; Miyamoto DT; Efstathiou JA
    Eur Urol; 2019 Jul; 76(1):71-72. PubMed ID: 30910345
    [No Abstract]   [Full Text] [Related]  

  • 9. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?" [Eur Urol 2023].
    Lenfant L; Pinar U; Rouprêt M; Seisen T
    Eur Urol; 2023 Jul; 84(1):e28-e30. PubMed ID: 37076399
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Madhuri Koti, Molly A. Ingersoll, Shilpa Gupta, et al. Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. Eur Urol Oncol 2020;3:622-30.
    Alfano M; Salonia A; Necchi A
    Eur Urol Oncol; 2020 Dec; 3(6):802-803. PubMed ID: 33153935
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].
    Alfred Witjes J; Bruins HM; Carrión A; Cathomas R; Compérat E; Efstathiou JA; Fietkau R; Gakis G; Lorch A; Martini A; Mertens LS; Meijer RP; Milowsky MI; Neuzillet Y; Panebiaco V; Redlef J; Rink M; Rouanne M; Thalmann GN; Sæbjørnsen S; Veskimäe E; Mariappan P; van der Heijden AG
    Eur Urol; 2024 Jun; 85(6):e180. PubMed ID: 38492977
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Vila-Reyes H; Joel DeCastro G; McKiernan JM
    Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum re "Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study" [Eur Urol 2012;62:797-802].
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2019 Mar; 75(3):e81. PubMed ID: 30409675
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Sven van den Bosch, J. Alfred Witjes. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011;60:493-500.
    Banerjee S; Kumar V
    Eur Urol; 2012 Mar; 61(3):e13. PubMed ID: 22206799
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420-33: A Statement from the International Bladder Cancer Network.
    Williams SB; Black PC; Dyrskjøt L; Seiler R; Schmitz-Dräger B; Nawroth R; Todenhöfer T; Kamat AM; Goebell PJ
    Eur Urol; 2020 Apr; 77(4):e105-e106. PubMed ID: 31787429
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Re: Kari A.O. Tikkinen, Anssi Auvinen. Does the Imprecise Definition of Overactive Bladder Serve Commercial Rather than Patient Interests? Eur Urol 2012;61:746-8. The Origin of the Term Overactive Bladder, Industry, and Patient Care" [Eur Urol 2012;61:749-50].
    Abrams P; Wein A
    Eur Urol; 2012 Aug; 62(2):e48. PubMed ID: 27989300
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply from authors re: Marko Babjuk. Second resection for non-muscle-invasive bladder carcinoma: current role and future perspectives. Eur Urol 2010;58:191-2 and Giacomo Novara, Vincenzo Ficarra. Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. Eur Urol 2010;58:193-4.
    Divrik RT; Sahin AF; Ergör G
    Eur Urol; 2010 Aug; 58(2):195-6. PubMed ID: 20471156
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer?
    Vila-Reyes H; DeCastro GJ; McKiernan JM
    Eur Urol; 2021 Jan; 79(1):e35-e36. PubMed ID: 32829975
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Stress Proteins and Cytokines are Urinary Biomarkers for Diagnosis and Staging of Bladder Cancer" [Eur Urol 2011;59:113-9].
    Margel D; Pevsner-Fischer M; Baniel J; Yossepowitch O; Cohen IR
    Eur Urol; 2011 Apr; 59(4):670. PubMed ID: 27989304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.